Characterization of Wnt1-inducible Signaling Pathway Protein-1 in Obese Children and Adolescents

Abstract

Wnt1-inducible signaling pathway protein-1 (WISP1), a member of the CCN family, is increasingly being recognized as a potential target for obesity and type 2 diabetes mellitus. Recent studies have shown that WISP1 can regulate low-grade inflammation in obese mice, and circulating WISP1 levels are associated with obesity and type 2 diabetes mellitus in adults. Herein, we measured serum WISP1 levels in obese youth and explored its relationships with pro-inflammatory cytokine interleukin 18 (IL-18) and other metabolic indexes. Totally, 44 normal-weight and 44 obese children and adolescents were enrolled. Physical and laboratory data were recorded, and then serum levels of WISP1 and IL-18 were determined by enzyme-linked immunosorbent assays. Results showed that serum levels of WISP1 were significantly higher in obese children and adolescents than in normal-weight healthy controls (1735.44±15.29 vs. 1364.08±18.69 pg/mL). WISP1 levels were significantly positively correlated with body mass index (BMI) and BMI z-score (r=0.392, P=0.008; r=0.474, P=0.001, respectively) in obese group; circulating IL-18 was increased in obese individuals (1229.06±29.42 vs. 295.87±13.30 pg/mL). Circulating WISP1 levels were significantly correlated with IL-18 (r=0.542, P<0.001), adiponectin (r=0.585, P<0.001) and leptin (r=0.592, P<0.001). The multivariate stepwise regression analysis showed that higher IL-18 levels represented the main determinant of increased WISP1 levels after adjusting for BMI, waist circumference, fasting insulin, homeostatic model assessment of insulin resistance (HOMA-IR) and HbA1c in obese individuals (β=0.542, P=0.000). WISP1 can be involved in glucose/lipid metabolism in obese youth, which may be modulated by IL-18. Increased WISP1 levels may be a risk factor of obesity and insulin resistance, and WISP1 has a potential therapeutic effect on insulin resistance in obese children and adolescents.

Keywords

Wnt1-inducible signaling pathway protein-1 / interleukin 18 / children and adolescents / insulin resistance / obesity

References

[1] NCD Risk Factor Collaboration NCD-RisC.. World trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measured studies in 1289 million children, adolescents, and adults. Lancet, 2017, 390(10113): 2627-2642

[2] KaplanskiG. Interleukin-18: biological properties and role in disease pathogenesis. Immunol Rev, 2018, 281(1): 138-153

[3] MaieseK. Programming apoptosis and autophagy with novel approaches for diabetes mellitus. Curr Neurovasc Res, 2015, 12(2): 173-188

[4] BlüherM, PfeifferAF, RudovichN. WISP1 is a novel adipokine linked to inflammation in obesity. Diabetes, 2015, 64(3): 856-866

[5] BarchettaI, CiminiFA, CapocciaD, et al.. WISP1 is a marker of systemic and adipose tissue inflammation in dysmetabolic subjects with or without type 2 diabetes. J Endocr Soc, 2017, 1(6): 660-670

[6] TackeC, AleksandrovaK, RehfeldtM, et al.. Assessment of circulating Wnt1 inducible signalling pathway protein 1 (WISP1)/CCN4 as a novel biomarker of obesity. J Cell Commun Signal, 2018, 12(3): 539-548

[7] Sahin ErsoyG, AltunEnsariT, SubasS, et al.. WISP1 is a novel adipokine linked to metabolic parameters in gestational diabetes mellitus. J Matern Fetal Neonatal Med, 2017, 30(8): 942-946

[8] BruunJM, StallknechtB, HelgeJW, et al.. Interleukin-18 in plasma and adipose tissue: effects of obesity, insulin resistance, and weight loss. Eur J Endocrinol, 2007, 157(4): 465-471

[9] ZaharievaE, KamenovZ, VelikovaT, et al.. Interleukin-18 serum level is elevated in type 2 diabetes and latent autoimmune diabetes. Endocr Connect, 2018, 7(1): 179-185

[10] ReddyVS, ValenteAJ, DelafontaineP, et al.. Interleukin-18/WNT1-inducible signaling pathway protein-1 signaling mediates human saphenous vein smooth muscle cell proliferation. J Cell Physiol, 2011, 226(12): 3303-3315

[11] BarlowSE, DietzWH. Obesity evaluation and treatment: Expert Committee recommendations. the maternal and child health bureau, health resources and services administration and department of health and human services. Pediatrics, 1998, 102(3): E29

[12] LiH, JiCY, ZongXN, et al.. Body mass index growth curves for Chinese children and adolescents aged 0 to 18 years. Zhonghua Er Ke Za Zhi (Chinese), 2009, 47(7): 493-498

[13] BrownRJ, YanovskiJA. Estimation of insulin sensitivity in children: methods, measures and controversies. Pediatr Diabetes, 2014, 15(3): 151-161

[14] WallaceTM, LevyJC, MatthewsDR. Use and abuse of HOMA modeling. Diabetes Care, 2004, 27(6): 1487-1495

[15] SongP, YuJ, ChangX, et al.. Prevalence and correlates of metabolic syndrome in Chinese children: the China health and nutrition survey. Nutrients, 2017, 9(1): E79

[16] WuS, GaoH, MaY, et al.. Characterisation of betatrophin concentrations in childhood and adolescent obesity and insulin resistance. Pediatr Diabetes, 2016, 17(1): 53-60

[17] BrigstockDR. The CCN family: a new stimulus package. J Endocrinol, 2003, 178(2): 169-175

[18] PennicaD, SwansonTA, WelshJW, et al.. WISP genes are members of the connective tissue growth factor family that are up-regulated in Wnt-1-transformed cells and aberrantly expressed in human colon tumors. Proc Natl Acad Sci USA, 1998, 95(25): 14717-14722

[19] Sahin ErsoyG A, EnsariT, VatanseverD, et al.. Novel adipokines WISP1 and betatrophin in PCOS: relationship to AMH levels, atherogenic and metabolic profile. Gynecol Endocrinol, 2017, 33(2): 119-123

[20] OkamuraH, TsutsiH, KomatsuT, et al.. Cloning of a new cytokine that induces IFN-gamma production by T cells. Nature, 1995, 378(6552): 88-91

[21] SkurkT, KolbH, Müller-ScholzeS, et al.. The proatherogenic cytokine interleukin-18 is secreted by human adipocytes. Eur J Endocrinol, 2005, 152(6): 863-868

[22] GarcíaVE, UyemuraK, SielingPA, et al.. IL-18 promotes type 1 cytokine production from NK cells and T cells in human intracellular infection. J Immunol, 1999, 162(10): 6114-6121

[23] PrestaI, AndreozziF, SuccurroE, et al.. IL-18 gene polymorphism and metabolic syndrome. Nutr Metab Cardiovasc Dis, 2009, 19(2): e5-6